MET and glioma: Recently, there have been two studies that have demonstrated that combination treatment with a c-Met inhibitor and TRAIL resulted in induction of apoptosis in glioma and papillary thyroid carcinomas, almost all of which were due to increased DR5 and inhibition of the activated c-Met pathway [23, 24].